OncoMatch/Clinical Trials/NCT03736863
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Is NCT03736863 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Apatinib+ SHR-1210（Camrelizumab） and Apatinib+ SHR-1316（Adebrelimab） for esophageal cancer.
Treatment: Apatinib+ SHR-1210（Camrelizumab） · Apatinib+ SHR-1316（Adebrelimab） · SHR-1316（Adebrelimab）+SHR-A2009 — The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy or immunotherapy — first-line
First-line patients who progressed or were intolerant after chemotherapy (cohort A) or immunotherapy (other cohorts). Concurrent chemoradiotherapy with postoperative recurrence or metastasis is considered as first-line treatment. For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, it should be counted as first-line treatment failure
Cannot have received: same type of drug as the drug in this study (except immune checkpoint inhibitors)
Those who have received the same type of drug as the drug in this study (except immune checkpoint inhibitors)
Lab requirements
Blood counts
HB ≥ 90 g/L; ANC ≥ 1.5 × 10^9/L; PLT ≥ 80 × 10^9/L
Kidney function
Plasma Cr ≤ 1.5 ULN or creatinine clearance rate (CCr) ≥ 60 mL/min
Liver function
ALT and AST ≤ 2.5 ULN; if there is no liver metastasis, ALT and AST ≤ 5 ULN; TBIL ≤ 1.5ULN; ALB ≥ 30 g/L
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%)
Adequate function of major organs defined as: (1) Routine blood test: a. HB ≥ 90 g/L; b. ANC ≥ 1.5 × 10^9/L; c. PLT ≥ 80 × 10^9/L; (2) Biochemical test: a. ALB ≥ 30 g/L; b. ALT and AST ≤ 2.5 ULN; if there is no liver metastasis, ALT and AST ≤ 5 ULN; c. TBIL ≤ 1.5ULN; d. Plasma Cr ≤ 1.5 ULN or creatinine clearance rate (CCr) ≥ 60 mL/min; Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify